Acadia CFO’s Latest Insider Trade Signals Confidence in Near‑Term Upside

Insider Activity at Acadia Pharmaceuticals: What Mark C. Schneyer’s Recent Trade Signals

The most recent insider filing from Acadia Pharmaceuticals shows EVP and Chief Financial Officer Mark C. Schneyer buying 5,849 shares at $17.84 on August 5, 2026. The transaction was executed under an employee‑stock‑purchase plan and now adds to a larger holding of 73,677 shares. This purchase follows a pattern of balanced buying and selling that has defined Schneyer’s recent insider activity.

A Pattern of Tactical Moves

Schneyer’s recent trading history reveals a mix of opportunistic buys and Rule 10b5‑1‑planned sales. In early August, he sold 5,849 shares at $29.00 under a 10b5‑1 plan while simultaneously buying the same number at the lower $17.84 purchase price. Earlier in the month, he executed a larger sale of 14,292 shares at the same $17.84 price and bought 5,000 shares at $29.00, a classic “sell‑buy” spread that often reflects a neutral market stance. Historically, his transactions have hovered around the $20–$25 range, with occasional large sales in March and May, and a notable block sale in September 2025. The pattern suggests he uses predetermined plans to manage liquidity while maintaining a net long position.

Implications for Investors

For investors, Schneyer’s net‑long approach signals confidence in Acadia’s trajectory. The fact that he is buying at a price roughly 20 % below the current market price ($28.45) indicates a belief that the stock is undervalued in the short term. His recent sales under 10b5‑1 plans, however, provide a buffer against insider speculation and demonstrate a disciplined risk‑management approach. The company’s strong quarterly earnings (P/E 13.16) and a 12.9 % weekly rally support the view that the share price may continue to climb, especially given Acadia’s pipeline in Parkinson’s and schizophrenia.

Who is Mark C. Schneyer?

Mark C. Schneyer has served as Acadia’s EVP, Chief Financial Officer since 2024, overseeing treasury, financial reporting, and investor relations. His insider trades—both purchases and sales—have typically been executed under Rule 10b5‑1 plans or employee‑stock‑purchase agreements, reflecting a preference for structured, long‑term participation rather than speculative short‑term trading. He has a history of buying shares when the company announces positive milestones or regulatory approvals, and selling when it needs to meet liquidity requirements or diversify holdings. His recent purchase at $17.84 coincides with a period of robust clinical‑trial activity, suggesting he is positioning himself for the company’s upcoming commercial launches.

Looking Ahead

Acadia’s recent 52‑week high of $29.48 and a 17.7 % year‑to‑date gain point to a bullish trend. With Schneyer’s net‑long stance, the company’s insider confidence is reinforced, potentially encouraging institutional investors to look favorably on the stock. As the company moves closer to launch dates for its Parkinson’s and schizophrenia candidates, the market may see further upside. For investors, watching Schneyer’s subsequent trades—especially any large sales or additional purchases—could offer a valuable barometer for Acadia’s near‑term outlook.